secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132736
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction
--------------------------------------------------------------------------------

- Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
- Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.
- Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.
- Trial continues blinded to assess eGFR over two years, expected completion in 2027.
- No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/0001193125-25-132736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer